Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
Fundamentals
Mkt Cap
$1.1B
Volume
-
52W High
$12.41
52W Low
$7.02
PE Ratio
-4.02
Avg. Volume
728,522.65
EPS (Annual)
-$1.81
P/B
2.22
Rev/Employee
$133,837.70
Earnings
Nov 17
52
Neutral Sentiment
How do you feel about IMTX?
NJgolfer
$IMTX Perceptive is one of the best biotech funds around. Glad to see they bought into the last share offering. 2027 should be a home run for $IMTX
2
RemitTekram
$IMTX I'm going to wake you up today. This is going places based on IOVA's demand and success.